STOCK TITAN

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial covid-19
Rhea-AI Summary

Vaxart, Inc. (Nasdaq: VXRT) announced that its Chief Scientific Officer, Dr. Sean Tucker, and Senior Scientist, Dr. Rebecca Flitter, will present data on its COVID-19 oral tablet vaccine at the International Congress of Mucosal Immunology 2022, scheduled for July 16-20 in Seattle. On July 18, Dr. Tucker will discuss oral vaccination's ability to induce pan-coronavirus nasal IgA responses, while Dr. Flitter will present findings on mucosal rAd5 immunization against SARS-CoV-2, showcasing its effectiveness in non-human primates.

Positive
  • Expert presentations at a significant immunology conference enhance credibility.
  • Potential breakthrough in oral vaccine delivery could attract investor interest.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.

Presentation Information:

Title: Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in Humans
Speaker: Dr. Sean Tucker
Date: Monday, July 18, 2022
Time: 11:00 a.m. PT / 2:00 p.m. ET

Title: Mucosal rAd5 Immunization against SARS-CoV-2 Spike Elicits Cross-Reactive Nasal and Serum Neutralizing Antibodies and Protects Against Beta Variant Challenge in Non-Human Primates
Speaker: Dr. Rebecca Flitter
Date: Monday, July 18, 2022
Time: 11:00 a.m. PT / 2:00 p.m. ET

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts              
  

Vaxart Media Relations: Investor Relations:     
Mark Herr   Andrew Blazier
Vaxart, Inc.   FINN Partners
mherr@vaxart.comIR@Vaxart.com
(203) 517-8957    (646) 871-8486   


FAQ

What will Vaxart present at the International Congress of Mucosal Immunology 2022?

Vaxart will present data on its COVID-19 oral tablet vaccine, highlighting its ability to induce immune responses.

When is Vaxart's presentation at the immunology congress?

Vaxart's presentation will take place on July 18, 2022.

Who will present Vaxart's research at the conference?

Dr. Sean Tucker and Dr. Rebecca Flitter will present the research findings.

What is the significance of Vaxart's oral tablet vaccine?

The oral tablet vaccine aims to provide a non-invasive method of vaccination, enhancing accessibility and safety.

Vaxart, Inc

NASDAQ:VXRT

VXRT Rankings

VXRT Latest News

VXRT Stock Data

136.47M
225.45M
0.87%
17.81%
4.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO